Operator Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz ...

BioNTech SE (BNTX) reports strong revenue growth and pipeline progress, while navigating financial and legal hurdles.

BioNTech SE (BNTX) has released an update. BioNTech SE reported a strong third quarter in 2024, with revenues reaching €1.2 ...

Jefferies analyst Akash Tewari maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $150.00.

BioNTech SE (BNTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yaron Werber ...

BioNTech (NASDAQ:BNTX – Get Free Report) will be announcing its earnings results before the market opens on Monday, November ...

German biotech BioNTech saw its shares rise more than 3% to $114.98 pre-market today, as it reported financial results for the three months ended September 30, 2024, that beat expectations. Revenues ...

BioNTech (BNTX) said on Monday that it expects full-year revenue at the low end of its guidance due in part to inventory write-downs, even as variant-adapted COVID-19 vaccines helped the German ...

As declining COVID-19 vaccine sales continue to hurt BioNTech’s top line, investors will be keen to get an update on BNTX’s revenue guidance for 2024 on the upcoming conference call.

BioNTech SE (NASDAQ:BNTX) has been notified by its partner, OncoC4 Inc., that the FDA has imposed a partial clinical hold on ...